Teva Launches Buprenorphine/Naloxone SL Tablets

Teva announced the launch of Buprenorphine HCl and Naloxone HCl Dihydrate Sublingual Tablets, the generic version of Reckitt Benckiser's Suboxone.

Buprenorphine HCl and Naloxone HCl Dihydrate are indicated for the maintenance treatment of opioid dependence. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is a potent antagonist at mu-opioid receptors and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally.

RELATED: Smartphone App to Monitor Opioid Addiction Tx: Clinical Trial Begins

Buprenorphine HCl and Naloxone HCl Dihydrate Sublingual Tablets are available in 2mg/0.5mg and 8mg/2mg strengths in 30-count bottles.

For more information call (888) 838-2872 or visit TevaGenerics.com.

Loading links....